23:07 , Jul 20, 2018 |  BioCentury  |  Regulation

FDA’s positive reinforcement

Companies are still sifting through a half dozen gene therapy guidance documents issued by FDA, but so far it appears the recommendations support the paths taken by some of the most advanced clinical candidates for...
13:01 , May 25, 2018 |  BioCentury  |  Product Development

Patients at the core

With excitement mounting for the seven hemophilia gene therapies in the clinic, the National Hemophilia Foundation wanted to avoid a scenario in which patients, physicians and payers had no good way to compare them. The...
16:17 , May 4, 2018 |  BC Week In Review  |  Financial News

uniQure raises $128.5M follow-on

Gene therapy company uniQure N.V. (NASDAQ:QURE) raised $128.5 million on May 3 in a follow-on through the sale of 4.5 million shares at $28.50. Leerink Partners, Evercore ISI, Wells Fargo Securities, Chardan, H.C. Wainwright &...
17:21 , May 3, 2018 |  BC Extra  |  Financial News

uniQure raises $128.5M follow-on

Gene therapy company uniQure N.V. (NASDAQ:QURE) raised $128.5 million in a follow-on Thursday through the sale of 4.5 million shares at $28.50. Leerink Partners, Evercore ISI, Wells Fargo Securities, Chardan, H.C. Wainwright & Co. and...
18:02 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

uniQure maps plan for hemophilia B gene therapy

uniQure N.V. (NASDAQ:QURE) rose 60% on Oct. 19 after the company said it will begin a Phase III trial next year of gene therapy AMT-061 to treat hemophilia B. The adeno-associated viral serotype 5 (AAV5)...
21:56 , Oct 19, 2017 |  BC Extra  |  Clinical News

uniQure maps plan for hemophilia B gene therapy

uniQure N.V. (NASDAQ:QURE) rose $5.69 (60%) to $15.16 after it said it will begin a Phase III trial next year of gene therapy AMT-061 to treat hemophilia B. The adeno-associated viral serotype 5 (AAV5) vector's...